Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
sell

Esperion Therapeutis.Inc. sell Bank of America Co.

Esperion Therapeutis.Inc.
Start price
€2.36
20.06.24 / 50%
Target price
€2.33
20.06.25
Performance (%)
-60.00%
End price
€0.94
21.06.25
Summary
This prediction ended on 21.06.25 with a price of €0.94. Bank_of_America_Co_ correctly predicted massive losses of -60.00% for Esperion Therapeutis.Inc.. Bank_of_America_Co_ has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y
Esperion Therapeutis.Inc. - - 57.643%
iShares Core DAX® -0,87 % 5,32 % 6,86 %
iShares Nasdaq 100 -0,38 % 1,98 % 25,70 %
iShares Nikkei 225® -1,68 % 1,95 % 41,44 %
iShares S&P 500 -0,65 % 2,07 % 21,40 %

Comments by Bank_of_America_Co_ for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren
Prediction Sell
Perf. (%) -60.00%
Target price 2.332
Change
Ends at 20.06.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $2.50 price target on the stock, down previously from $2.90.
Ratings data for ESPR provided by MarketBeat

Bank of America Co. 
0
Report Share
20.06.24
In the thread Trading Esperion Therapeutis.Inc.
Prediction Sell
Perf. (%) -60.00%
Target price 2.332
Change
Ends at 20.06.25

Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten

Bank of America Co. 
0
Report Share
21.06.25

Stopped prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.27
15.06.23
€3.68
15.06.24
111.30%
16.06.24

Bank of America Co. 
15.06.23 50%